Nanoparticles Overcome Anticancer Drug Resistance

June 12, 2006

Too often, chemotherapy fails to cure cancer because some tumor cells develop resistance to multiple anticancer drugs. In most cases, resistance develops when cancer cells begin expressing a protein, known as p-glycoprotein, that is capable of pumping anticancer drugs out of a cell as quickly as they cross through the cell’s outer membrane. New research from the University of Kentucky shows that nanoparticles may be able to get anticancer drugs into cells without triggering the p-glycoprotein pump.

Writing in the Journal of Controlled Release, a team led by Russell Mumper, Ph.D., describes its work using untargeted nanoparticles made of cetyl alcohol and polysorbate, which the investigators have named E78 nanoparticles, as a delivery vehicle for the potent anticancer drug paclitaxel. Biodistribution studies with the formulation and with free paclitaxel revealed few significant differences in which the active drug ends up in the body.

Next, the investigators injected the nanoparticle-entrapped paclitaxel, empty nanoparticles, free paclitaxel, or saline directly into paclitaxel-resistant human colon tumors growing in mice. Nineteen days after injection, tumors in the animals treated with nanoparticle-entrapped paclitaxel were 47 percent smaller than those treated with free paclitaxel and 70 percent smaller than those in animals treated with plain nanoparticles or saline.

One surprising finding from this study was the fact that free paclitaxel had any effect at all on tumors known to be resistant to the drug. Further investigation showed that this effect was likely a result of paclitaxel’s ability to inhibit angiogenesis. The researchers concluded that nanoparticulate-entrapped paclitaxel was able to suppress tumor growth by killing tumor cells directly and through inhibition of angiogenesis.

This work is detailed in a paper titled, “In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors.” Based in part on these results, the NCI is now funding further work with a tumor-targeted version of this nanoparticle to determine if it can be used to overcome drug resistance in breast cancer patients. An abstract of this paper is available through PubMed.

Source: National Cancer Institute

Explore further: Expandable nanoparticles show promise in treating lethal abdominal cavity tumors

Related Stories

Nanoparticles may enhance cancer therapy

February 16, 2012

A mixture of current drugs and carbon nanoparticles shows potential to enhance treatment for head-and-neck cancers, especially when combined with radiation therapy, according to new research by Rice University and the University ...

Recommended for you

Physicists develop new technique to fathom 'smart' materials

November 26, 2015

Physicists from the FOM Foundation and Leiden University have found a way to better understand the properties of manmade 'smart' materials. Their method reveals how stacked layers in such a material work together to bring ...

Mathematicians identify limits to heat flow at the nanoscale

November 24, 2015

How much heat can two bodies exchange without touching? For over a century, scientists have been able to answer this question for virtually any pair of objects in the macroscopic world, from the rate at which a campfire can ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.